PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 27995057-7 2017 This is the first case to demonstrate the efficacy of PMX-DHP for rapidly progressive ILD with anti-MDA-5 antibody-positive CADM and a malignancy. pmx-dhp 54-61 interferon induced with helicase C domain 1 Homo sapiens 100-105 29065861-11 2017 A higher P/F ratio and SP-D level, lower LDH and ferritin levels, higher platelet counts, and anti-MDA-5 antibody negativity are important prognostic markers in patients with CADM-associated RPIPs treated with PMX-DHP. pmx-dhp 210-217 interferon induced with helicase C domain 1 Homo sapiens 99-104 27623356-4 2017 Following PMX-DHP, there were decreases from day 0 day 1 day 2 in both the mean plasma sPLA2 -II level (340 260 189 ng/mL) and plasma SP-D level (483 363 252 ng/mL). pmx-dhp 10-17 phospholipase A2 group IIA Homo sapiens 91-96 27623356-4 2017 Following PMX-DHP, there were decreases from day 0 day 1 day 2 in both the mean plasma sPLA2 -II level (340 260 189 ng/mL) and plasma SP-D level (483 363 252 ng/mL). pmx-dhp 10-17 surfactant protein D Homo sapiens 142-146 27623356-8 2017 The results suggest that as the blood endotoxin levels were lowered by the PMX-DHP, the inflammatory reactions were suppressed, with suppressed formation of sPLA2 -II and improved pulmonary oxygenation potential. pmx-dhp 75-82 phospholipase A2 group IIA Homo sapiens 157-162 24965294-5 2014 The serum soluble VE-cadherin level of septic patients before PMX-DHP was 3424.1 +- 2033.0 ng/mL, which was significantly lower than that of the controls (5862.0 +- 1521.2 ng/mL; P < 0.0001). pmx-dhp 62-69 cadherin 5 Homo sapiens 18-29 26710929-0 2016 Effect of PMX-DHP for sepsis due to ESBL-producing E. coli in an extremely low-birthweight infant. pmx-dhp 10-17 EsbL Escherichia coli 36-40 19260559-7 2008 In both groups, mBP and CAI increased significantly following PMX-DHP. pmx-dhp 62-69 myelin basic protein Mus musculus 16-19 19994591-8 2009 In 4 patients who survived for 60 days or longer, serum levels of LDH, CRP, and SP-D were significantly decreased after PMX-DHP, whereas KL-6 level was unchanged. pmx-dhp 120-127 C-reactive protein Homo sapiens 71-74 19994591-8 2009 In 4 patients who survived for 60 days or longer, serum levels of LDH, CRP, and SP-D were significantly decreased after PMX-DHP, whereas KL-6 level was unchanged. pmx-dhp 120-127 surfactant protein D Homo sapiens 80-84 19994591-10 2009 These data suggest that serum levels of LDH, CRP, and SP-D might be predictive of successful PMX-DHP treatment in cases of IP-AE. pmx-dhp 93-100 C-reactive protein Homo sapiens 45-48 19994591-10 2009 These data suggest that serum levels of LDH, CRP, and SP-D might be predictive of successful PMX-DHP treatment in cases of IP-AE. pmx-dhp 93-100 surfactant protein D Homo sapiens 54-58 24593215-3 2014 After PMX-DHP treatment, the PaO2/FiO2 ratio and serum LDH and KL-6 were improved, the abnormal shadows in chest high-resolution computed tomography (HRCT) scans gradually decreased, and, finally, all patients survived. pmx-dhp 6-13 mucin 1, cell surface associated Homo sapiens 63-67 24297126-5 2013 To our knowledge, this is the first case to indicate a serial reduction of anti-CADM-140/MDA5 autoantibodies, associated with clinical improvement, following PMX-DHP. pmx-dhp 158-165 interferon induced with helicase C domain 1 Homo sapiens 89-93 22117502-9 2011 Serum levels of Interleukin (IL)-7, an anti-fibrotic cytokine, in survivors at day 30 following PMX-DHP therapy ("Survivors") significantly increased after the treatment, compared to serum levels of non-survivors at day 30 after the therapy ("Nonsurvivors"), which did not demonstrate a significant change. pmx-dhp 96-103 interleukin 7 Homo sapiens 16-34 22117502-11 2011 Multivariate Cox proportional-hazards analysis showed that an increase in IL-7 levels after PMX-DHP therapy and treatment without intubation (other than invasive positive-pressure ventilation) were significantly better prognostic factors. pmx-dhp 92-99 interleukin 7 Homo sapiens 74-78 22117502-12 2011 CONCLUSION: The results suggest that serum IL-7 may be a useful prognostic factor for patients with AE of IPF treated with PMX-DHP, possibly reflecting underlying anti-fibrotic mechanisms. pmx-dhp 123-130 interleukin 7 Homo sapiens 43-47 21124011-9 2011 The serum level of monocyte chemotactic protein 1 was significantly decreased immediately after PMX-DHP. pmx-dhp 96-103 C-C motif chemokine ligand 2 Homo sapiens 19-49 33853291-11 2021 After PMX-DHP, the mean P/F ratio improved (86 [range, 63-106] vs. 145 [86-260], P=0.030) and interleukin-6 and c-reactive protein decreased (79 [35-640] vs. 10 [5-25], P=0.018 and 14 [4-21] vs. 5 [2-6], P=0.019, respectively). pmx-dhp 6-13 interleukin 6 Homo sapiens 94-107 35525835-11 2022 Although PMX-DHP significantly reduced eotaxin and GM-CSF serum levels (P < 0.01 and P < 0.05), these levels did not change after treatment. pmx-dhp 9-16 C-C motif chemokine ligand 11 Homo sapiens 39-46 35525835-11 2022 Although PMX-DHP significantly reduced eotaxin and GM-CSF serum levels (P < 0.01 and P < 0.05), these levels did not change after treatment. pmx-dhp 9-16 colony stimulating factor 2 Homo sapiens 51-57 35566611-8 2022 Also, white blood cells (WBCs) and C-reactive protein (CRP) were decreased after PMX-DHP treatment. pmx-dhp 81-88 C-reactive protein Homo sapiens 35-53 35566611-8 2022 Also, white blood cells (WBCs) and C-reactive protein (CRP) were decreased after PMX-DHP treatment. pmx-dhp 81-88 C-reactive protein Homo sapiens 55-58 16556131-10 2006 The TNF-alpha production capacity of whole blood, which was found to be lower in the septic shock patients than in healthy subjects, was significantly increased after PMX-DHP. pmx-dhp 167-174 tumor necrosis factor Homo sapiens 4-13 33853291-11 2021 After PMX-DHP, the mean P/F ratio improved (86 [range, 63-106] vs. 145 [86-260], P=0.030) and interleukin-6 and c-reactive protein decreased (79 [35-640] vs. 10 [5-25], P=0.018 and 14 [4-21] vs. 5 [2-6], P=0.019, respectively). pmx-dhp 6-13 C-reactive protein Homo sapiens 112-130 33423442-9 2020 PMX-DHP subsequently improved oxygenation (PaO2/FiO2 ratio) and decreased the levels of inflammatory markers (interleukin-6, C-reactive protein, and white blood cells). pmx-dhp 0-7 interleukin 6 Homo sapiens 110-123 33423442-9 2020 PMX-DHP subsequently improved oxygenation (PaO2/FiO2 ratio) and decreased the levels of inflammatory markers (interleukin-6, C-reactive protein, and white blood cells). pmx-dhp 0-7 C-reactive protein Homo sapiens 125-143